Woodline Partners’s OnKure Therapeutics OKUR Stock Holding History
Bought
Maintained
Sold
Other funds holding OKUR
NMC
TCM
CG
RVM
OCA
BCM
HCM
ACM
Woodline Partners's OKUR Position: Q4 2023 in Review
Woodline Partners sold out of OnKure Therapeutics (OKUR) in Q4 2023, closing a stake of 45,065 shares — an estimated $3.43M sold.
Woodline Partners first reported a position in OKUR in Q2 2023 and held it in 2 quarters. The position peaked at $3.43M in Q3 2023. 68 funds tracked by Wall St. Rank hold OKUR as of Q4 2023.
- Woodline Partners reported no remaining OnKure Therapeutics position as of Q4 2023 after selling out during the quarter.
- Woodline Partners sold 45,065 OnKure Therapeutics shares in Q4 2023, an estimated $3.43M.
- Woodline Partners first reported a position in OnKure Therapeutics in Q2 2023 and held it in 2 quarters.
- Woodline Partners's OnKure Therapeutics position peaked at $3.43M in Q3 2023.
- 68 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q4 2023.
Based on Woodline Partners's 13F filing for Q4 2023, filed 14 Feb 2024.